Amar M Salam1, Ebru Ertekin2, Iris M van Hagen2, Jassim Al Suwaidi1, Titia P E Ruys2, Mark R Johnson3, Lina Gumbiene4, Alexandra A Frogoudaki5, Khaled A Sorour6, Laurence Iserin7, Magalie Ladouceur7, A Carla C van Oppen8, Roger Hall9, Jolien W Roos-Hesselink10. 1. Hamad Medical Corporation, Doha, Qatar. 2. Erasmus Medical Center, Rotterdam, the Netherlands. 3. Imperial College School of Medicine, Chelsea and Westminster Hospital, London, United Kingdom. 4. Vilnius University Hospital Santariskiu Klinikos, Vilnius University, Vilnius, Lithuania. 5. Attikon University Hospital, Second Cardiology Department, Athens University, Athens, Greece. 6. Kasr AL-Aini Hospitals, Cairo University, Cairo, Egypt. 7. Necker Hospital and Georges Pompidou European Hospital, Assistance publique-Hôpitaux de Paris, Paris, France. 8. University Medical Center, Utrecht, the Netherlands. 9. Norwich Medical School, University of East Anglia, Norwich, United Kingdom. 10. Erasmus Medical Center, Rotterdam, the Netherlands. Electronic address: j.roos@erasmusmc.nl.
Abstract
OBJECTIVES: Atrial fibrillation (AF)/atrial flutter (AFL) during pregnancy in these women is associated with adverse outcome of pregnancy. BACKGROUND: The incidence, timing, and consequences of AF or AFL during pregnancy in patients with heart disease are not well known. METHODS: Between January 2008 to June 2011, 60 hospitals in 28 countries prospectively enrolled 1,321 pregnant women with congenital heart disease, valvular heart disease, ischemic heart disease, or cardiomyopathy in the ROPAC (Registry of Pregnancy and Cardiac Disease). We studied the incidence, onset, and predictors of AF/AFL during pregnancy and assessed the pregnancy outcome. An overview of the existing literature is provided. RESULTS: Seventeen women (1.3%) developed AF/AFL during pregnancy, mainly in the second trimester (61.5%). Univariable analysis identified the following pre-pregnancy risk factors for AF/AFL in pregnancy: AF/AFL before pregnancy (odds ratio [OR]: 7.1, 95% confidence interval [CI]: 1.5 to 32.8); mitral valvular heart disease (OR: 6.9, 95% CI: 2.6 to 18.3); beta-blocker use (OR: 3.3, 95% CI: 1.2 to 9.0); and left-sided lesions (OR: 2.9, 95% CI: 1.0 to 8.3). Maternal mortality was higher in women with than in women without AF/AFL (11.8% vs. 0.9%; p = 0.01), although heart failure was not seen more often. Low birth weight (<2,500 g) occurred more often in women with than in women without AF/AFL (35% vs. 14%; p = 0.02). CONCLUSIONS: AF/AFL occurs in 1.3% of pregnant patients with structural heart disease with a peak at the end of the second trimester. AF/AFL during pregnancy in cardiac patients is associated with unfavorable maternal outcome and also has an impact on fetal birth weight.
OBJECTIVES:Atrial fibrillation (AF)/atrial flutter (AFL) during pregnancy in these women is associated with adverse outcome of pregnancy. BACKGROUND: The incidence, timing, and consequences of AF or AFL during pregnancy in patients with heart disease are not well known. METHODS: Between January 2008 to June 2011, 60 hospitals in 28 countries prospectively enrolled 1,321 pregnant women with congenital heart disease, valvular heart disease, ischemic heart disease, or cardiomyopathy in the ROPAC (Registry of Pregnancy and Cardiac Disease). We studied the incidence, onset, and predictors of AF/AFL during pregnancy and assessed the pregnancy outcome. An overview of the existing literature is provided. RESULTS: Seventeen women (1.3%) developed AF/AFL during pregnancy, mainly in the second trimester (61.5%). Univariable analysis identified the following pre-pregnancy risk factors for AF/AFL in pregnancy: AF/AFL before pregnancy (odds ratio [OR]: 7.1, 95% confidence interval [CI]: 1.5 to 32.8); mitral valvular heart disease (OR: 6.9, 95% CI: 2.6 to 18.3); beta-blocker use (OR: 3.3, 95% CI: 1.2 to 9.0); and left-sided lesions (OR: 2.9, 95% CI: 1.0 to 8.3). Maternal mortality was higher in women with than in women without AF/AFL (11.8% vs. 0.9%; p = 0.01), although heart failure was not seen more often. Low birth weight (<2,500 g) occurred more often in women with than in women without AF/AFL (35% vs. 14%; p = 0.02). CONCLUSIONS:AF/AFL occurs in 1.3% of pregnant patients with structural heart disease with a peak at the end of the second trimester. AF/AFL during pregnancy in cardiacpatients is associated with unfavorable maternal outcome and also has an impact on fetal birth weight.
Authors: Sofia E Gomez; Muhammad Fazal; Julio C Nunes; Shayena Shah; Alexander C Perino; Sanjiv M Narayan; Kamala P Tamirisa; Janet K Han; Fatima Rodriguez; Tina Baykaner Journal: J Interv Card Electrophysiol Date: 2022-10-13 Impact factor: 1.759
Authors: Annabelle Santos Volgman; Emelia J Benjamin; Anne B Curtis; Margaret C Fang; Kathryn J Lindley; Gerald V Naccarelli; Carl J Pepine; Odayme Quesada; Marmar Vaseghi; Albert L Waldo; Nanette K Wenger; Andrea M Russo Journal: J Cardiovasc Electrophysiol Date: 2020-12-29 Impact factor: 2.942
Authors: Kamala P Tamirisa; Cicely Dye; Rachel M Bond; Lisa M Hollier; Karolina Marinescu; Marmar Vaseghi; Andrea M Russo; Martha Gulati; Annabelle Santos Volgman Journal: J Cardiovasc Dev Dis Date: 2022-06-24